As a measure of clinical relevance, using a retrospective database analysis, the authors found that the use of bile acid sequestrants in humans was associated with reduced gastric cancer risk, and expression of a bile acid receptor, TGR5, paralleled disease severity. The gene discussed is GPBAR1; the disease is gastric cancer.